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Macrophages are highly variable, and their ontog-
eny and functions depend on the particular organ 
in which they reside and on any ongoing disease 
processes. Lung macrophages are critically im-
portant to lung function, and knowledge of their 
ontogeny and phenotypes is rapidly expanding. 
Lung macrophages are present within the alveo-
lar spaces and in the airway wall and lumen. Air-
way macrophages represent both alveolar macro-
phages that are on their way along the mucociliary 
escalator toward the nasopharynx and other dis-
tinct populations of macrophages, which may have 
their own ontogeny and function. In healthy lungs, 
the overarching functions of macrophages include 
serving as a host-defense surveillance system that 
protects the lungs, modulating (often dampening) 
inflammatory and immune responses, and mon-
itoring and regulating the surfactant layer, which 
is critical to maintaining a low surface tension and 
enabling the opening of alveoli with each breath.
In disease, lung macrophages play widely var-
ied roles. They can initiate inflammatory re-
sponses to gaseous, particulate, and microbial 
threats, facilitate the resolution of inflammatory 
and innate immune reactions, and participate in 
fibrotic or granulomatous reactions that result 
in alveolar or airway remodeling and defects in 
lung function.
The alveolar surfactant lining layer is tightly 
and continuously regulated by means of the pro-
duction of surfactant phospholipids and proteins 
by the type II alveolar epithelial cells and by means 
of the clearance of ineffective, often oxidized, 
surfactant by the alveolar macrophages. Cell sig-
naling initiated by the granulocyte–macrophage 
colony-stimulating factor (GM-CSF) receptor is 
critical to the breakdown of surfactant by macro-
phages. Pulmonary alveolar proteinosis is caused 
by defective signaling by the GM-CSF receptor, 
usually owing to a genetic deficiency that results 
in the diminished expression or function of the 
α or β subunits of the GM-CSF receptor or, more 
commonly, to autoantibodies against GM-CSF, 
resulting in defective clearance of surfactant lipo-
protein from the alveolar space. The distal lung 
tissue becomes filled with many massively en-
larged alveolar macrophages that are able to in-
gest surfactant but unable to process it. Ultimately, 
decreased gaseous exchange results in hypoxemic 
respiratory failure and defects in host defense. 
The human disease is closely mimicked — both 
structurally and physiologically — by deficiency 
of the GM-CSF receptor in mice, a disease model 
obtained by means of knockout of Csf2rb, which 
encodes the β subunit of GM-CSF.
Kleff and colleagues1 found that reconstitut-
ing the bone marrow of these mice with murine 
Csf2rb−/− hematopoietic stem cells that were ge-
netically engineered to express the mouse GM-CSF 
receptor completely reversed the lung pathology 
of surfactant accumulation within 12 weeks, de-
spite modest transduction levels of 10 to 20% 
(i.e., only a small fraction of the donor cells ex-
pressed the construct). Pulmonary alveolar pro-
teinosis developed in mice that were engineered 
to replace the murine GM-CSF protein with the 
human GM-CSF protein, because human GM-CSF 
is not recognized by the mouse GM-CSF receptor. 
The phenotype of this model of pulmonary alveo-
lar proteinosis was ameliorated when the bone 
marrow of mice was reconstituted with human 
CD34+ cells (from which macrophages differen-
tiate).2 These studies show that replacement with 
functional bone marrow–derived macrophages 
restores surfactant homeostasis. But in humans, 
the morbidity and mortality of bone marrow abla-
tion and transplantation limit their usefulness.
The possibility of transplanting macrophages, 
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Figure 1. A Potential Path to Pulmonary Macrophage Transplantation.
A schema for an approach to pulmonary macrophage transplantation in humans is suggested by several studies of 
mouse models of pulmonary alveolar proteinosis. It involves the isolation and differentiation of macrophages from 
CD34+ bone marrow cells. Alternatively, induced pluripotent stem cells could be generated from blood mononucle-
ar cells or CD34+ bone marrow cells. These macrophages or induced pluripotent stem cells could then be transfect-
ed with the gene or genes of interest and an appropriate regulatory signaling system. In the case of pulmonary alve-
olar proteinosis, transfection with CSF2RB (encoding the granulocyte–macrophage colony-stimulating factor 
[GM-CSF] receptor) would probably be most effective. These macrophages could then be transplanted into the tra-
chea or proximal or distal bronchi by means of bronchoscopic visualization of the airways and instillation. Effective 
treatment would depend on engraftment of these modified cells.
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perhaps after genetically manipulating them, by 
directly introducing them into a patient’s lungs 
and thus effecting repair of lung injury has long 
been a goal. A combined gene-and-cell approach 
has the potential to benefit patients with a wide 
range of lung diseases, including hereditary pul-
monary alveolar proteinosis (Fig. 1). Three stud-
ies bring this goal closer, at least for patients 
with pulmonary alveolar proteinosis. Happle et 
al.3 transplanted bone marrow–derived macro-
phage progenitors from wild-type mice into the 
airways of Csf2rb−/− mice and found that these 
progenitors abrogated the mice’s phenotype for 
pulmonary alveolar proteinosis and were detected 
only in the lungs from 5 weeks to 9 months after 
transplantation. Second, the other model of pul-
monary alveolar proteinosis, humanized mice 
expressing the human interleukin-3 and GM-CSF 
genes, was effectively treated by intrapulmonary 
transplantation of cells derived from CD34+ cells 
isolated from human cord blood.
Third, Suzuki et al.4 found that the transplan-
tation of bone marrow–derived, wild-type, highly 
purified, mature macrophages into the lungs of 
Csf2rb−/− mice resulted in proliferation of these 
macrophages, replacement of the Csf2rb−/− alveo-
lar macrophages, and reversal of the lung disease. 
Moreover, the progeny of these macrophages 
were present in the lungs 1 year after transplan-
tation. Suzuki et al. also found that the trans-
plantation of bone marrow–derived Csf2rb−/− mac-
rophages corrected by lentivirus-mediated Csf2rb 
complementary DNA expression abrogated pul-
monary alveolar proteinosis in Csf2rb−/− mice. 
Both wild-type and Csf2rb-corrected macrophages 
lost features of bone marrow macrophages and 
gained those of tissue-resident lung macrophages, 
a finding that is consistent with previous obser-
vations that the lung microenvironment is critical 
in determining the phenotype and function of 
macrophages. These studies suggest that autolo-
gous, gene-corrected, bone marrow–derived mac-
rophages represent a potential therapeutic inter-
vention for patients with the hereditary form of 
pulmonary alveolar proteinosis. Lachmann and 
colleagues have already generated patient-specif-
ic, gene-corrected, induced pluripotent stem cells.5
A clinical trial of pulmonary macrophage trans-
plantation in patients with pulmonary alveolar 
proteinosis is warranted. There are many possi-
bilities for this combined cell–gene therapy to 
benefit our patients. Macrophages that are ge-
netically engineered to regulate oxidative stress 
or enzymatic degradation may serve therapeutic 
purposes. One might envision the transplantation 
of macrophages that express genes encoding pro-
teins that down-regulate or even break down fi-
brotic tissue in diseases such as interstitial lung 
disease or pulmonary fibrosis. Macrophages that 
are engineered to inhibit proteases or to secrete 
matrix materials or building blocks may be valu-
able in diseases such as emphysema. Macrophages 
that possess ion channels that can modulate the 
hydration of airway liquid may be helpful in the 
many common diseases (e.g., chronic bronchitis 
and cystic fibrosis) in which abnormal viscoelas-
tic properties of sputum alter epithelial responses 
and host defense. The current focus on airway 
exosomes (minute, cell-derived vesicles that can 
transfer genes and proteins from one cell type to 
another) brings to mind the possibility that 
macrophages that have been engineered to ex-
press the messenger RNA of the gene encoding 
the cystic fibrosis transmembrane conductance 
regulator (CFTR) could be used to treat patients 
with cystic fibrosis. All that being said, caution 
is, of course, needed: the long lifetime of these 
macrophages and their ability to proliferate and 
alter lung homeostasis raise concerns about safety. 
In sum, the opportunities for pulmonary macro-
phage transplantation are many and are worthy 
of further exploration.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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